p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis

Monica Schiappacassi, Francesca Lovat, Vincenzo Canzonieri, Barbara Belletti, Stefania Berton, Domenica Di Stefano, Andrea Vecchione, Alfonso Colombatti, Gustavo Baldassarre

Research output: Contribution to journalArticle

Abstract

The tumor suppressor gene CDKN1B encodes for a 27-kDa cyclin-dependent kinase inhibitory protein, p27Kip1, which together with its well-established role in the inhibition of cell proliferation, displays additional activities in the control of gene transcription and cell motility. p27Kip1 thus represents a good candidate for a gene therapy approach, especially in those cancers refractory to the conventional therapies, like human glioblastoma. Here, we show that overexpression of p27Kip1 in glioblastoma cell lines induced cell cycle arrest and inhibition of cell motility through extracellular matrix substrates. The use of adenoviral vectors in the treatment of glioblastoma in vivo showed that p27Kip1 was able to block not only cancer cell growth but also local invasion and tumor-induced neoangiogenesis. The latter effect was due to the ability of p27 to impair both endothelial cell growth and motility, thus preventing proper vessel formation in the tumor. The block of neoangiogenesis depended on cytoplasmic p27 Kip1 antimigratory activity and was linked to its ability to bind to and inhibit the microtubule-destabilizing protein stathmin. Our work provides the first evidence that a successful p27Kip1-based gene therapy is linked to tumor microenvironment modification, thus opening new perspectives to the use of gene therapy approaches for the treatment of refractory cancers.

Original languageEnglish
Pages (from-to)1164-1175
Number of pages12
JournalMolecular Cancer Therapeutics
Volume7
Issue number5
DOIs
Publication statusPublished - 2008

Fingerprint

Glioblastoma
Genetic Therapy
Cell Movement
Growth
Neoplasms
Stathmin
Microtubule Proteins
Tumor Microenvironment
Cyclin-Dependent Kinases
Cell Cycle Checkpoints
Tumor Suppressor Genes
Extracellular Matrix
Therapeutics
Endothelial Cells
Cell Proliferation
Cell Line
Genes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Drug Discovery
  • Pharmacology

Cite this

p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis. / Schiappacassi, Monica; Lovat, Francesca; Canzonieri, Vincenzo; Belletti, Barbara; Berton, Stefania; Di Stefano, Domenica; Vecchione, Andrea; Colombatti, Alfonso; Baldassarre, Gustavo.

In: Molecular Cancer Therapeutics, Vol. 7, No. 5, 2008, p. 1164-1175.

Research output: Contribution to journalArticle

Schiappacassi, Monica ; Lovat, Francesca ; Canzonieri, Vincenzo ; Belletti, Barbara ; Berton, Stefania ; Di Stefano, Domenica ; Vecchione, Andrea ; Colombatti, Alfonso ; Baldassarre, Gustavo. / p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis. In: Molecular Cancer Therapeutics. 2008 ; Vol. 7, No. 5. pp. 1164-1175.
@article{6d705c42dd46439cac16d6f2821ab2cf,
title = "p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis",
abstract = "The tumor suppressor gene CDKN1B encodes for a 27-kDa cyclin-dependent kinase inhibitory protein, p27Kip1, which together with its well-established role in the inhibition of cell proliferation, displays additional activities in the control of gene transcription and cell motility. p27Kip1 thus represents a good candidate for a gene therapy approach, especially in those cancers refractory to the conventional therapies, like human glioblastoma. Here, we show that overexpression of p27Kip1 in glioblastoma cell lines induced cell cycle arrest and inhibition of cell motility through extracellular matrix substrates. The use of adenoviral vectors in the treatment of glioblastoma in vivo showed that p27Kip1 was able to block not only cancer cell growth but also local invasion and tumor-induced neoangiogenesis. The latter effect was due to the ability of p27 to impair both endothelial cell growth and motility, thus preventing proper vessel formation in the tumor. The block of neoangiogenesis depended on cytoplasmic p27 Kip1 antimigratory activity and was linked to its ability to bind to and inhibit the microtubule-destabilizing protein stathmin. Our work provides the first evidence that a successful p27Kip1-based gene therapy is linked to tumor microenvironment modification, thus opening new perspectives to the use of gene therapy approaches for the treatment of refractory cancers.",
author = "Monica Schiappacassi and Francesca Lovat and Vincenzo Canzonieri and Barbara Belletti and Stefania Berton and {Di Stefano}, Domenica and Andrea Vecchione and Alfonso Colombatti and Gustavo Baldassarre",
year = "2008",
doi = "10.1158/1535-7163.MCT-07-2154",
language = "English",
volume = "7",
pages = "1164--1175",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis

AU - Schiappacassi, Monica

AU - Lovat, Francesca

AU - Canzonieri, Vincenzo

AU - Belletti, Barbara

AU - Berton, Stefania

AU - Di Stefano, Domenica

AU - Vecchione, Andrea

AU - Colombatti, Alfonso

AU - Baldassarre, Gustavo

PY - 2008

Y1 - 2008

N2 - The tumor suppressor gene CDKN1B encodes for a 27-kDa cyclin-dependent kinase inhibitory protein, p27Kip1, which together with its well-established role in the inhibition of cell proliferation, displays additional activities in the control of gene transcription and cell motility. p27Kip1 thus represents a good candidate for a gene therapy approach, especially in those cancers refractory to the conventional therapies, like human glioblastoma. Here, we show that overexpression of p27Kip1 in glioblastoma cell lines induced cell cycle arrest and inhibition of cell motility through extracellular matrix substrates. The use of adenoviral vectors in the treatment of glioblastoma in vivo showed that p27Kip1 was able to block not only cancer cell growth but also local invasion and tumor-induced neoangiogenesis. The latter effect was due to the ability of p27 to impair both endothelial cell growth and motility, thus preventing proper vessel formation in the tumor. The block of neoangiogenesis depended on cytoplasmic p27 Kip1 antimigratory activity and was linked to its ability to bind to and inhibit the microtubule-destabilizing protein stathmin. Our work provides the first evidence that a successful p27Kip1-based gene therapy is linked to tumor microenvironment modification, thus opening new perspectives to the use of gene therapy approaches for the treatment of refractory cancers.

AB - The tumor suppressor gene CDKN1B encodes for a 27-kDa cyclin-dependent kinase inhibitory protein, p27Kip1, which together with its well-established role in the inhibition of cell proliferation, displays additional activities in the control of gene transcription and cell motility. p27Kip1 thus represents a good candidate for a gene therapy approach, especially in those cancers refractory to the conventional therapies, like human glioblastoma. Here, we show that overexpression of p27Kip1 in glioblastoma cell lines induced cell cycle arrest and inhibition of cell motility through extracellular matrix substrates. The use of adenoviral vectors in the treatment of glioblastoma in vivo showed that p27Kip1 was able to block not only cancer cell growth but also local invasion and tumor-induced neoangiogenesis. The latter effect was due to the ability of p27 to impair both endothelial cell growth and motility, thus preventing proper vessel formation in the tumor. The block of neoangiogenesis depended on cytoplasmic p27 Kip1 antimigratory activity and was linked to its ability to bind to and inhibit the microtubule-destabilizing protein stathmin. Our work provides the first evidence that a successful p27Kip1-based gene therapy is linked to tumor microenvironment modification, thus opening new perspectives to the use of gene therapy approaches for the treatment of refractory cancers.

UR - http://www.scopus.com/inward/record.url?scp=49849088123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49849088123&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-07-2154

DO - 10.1158/1535-7163.MCT-07-2154

M3 - Article

C2 - 18483304

AN - SCOPUS:49849088123

VL - 7

SP - 1164

EP - 1175

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -